PhotoPharmics, a Utah-based medtech firm, advances Celeste, a non-invasive phototherapy device targeting circadian rhythms and mitochondrial function to address both motor and non-motor Parkinson’s symptoms. The company’s $6 million Series B extension and ongoing Phase 3 ‘Light for PD’ trial support FDA submission and broader patient access.

Key points

• PhotoPharmics closes an oversubscribed $6 million Series B extension
• Celeste delivers specialized light wavelengths to the retina to modulate circadian and mitochondrial function
• Ongoing Phase 3 ‘Light for PD’ trial enrolls over 200 Parkinson’s patients
• Device design supports daily passive use at home without systemic monitoring
• FDA grants Celeste Breakthrough Device Designation to expedite review

Why it matters: By targeting underlying circadian and mitochondrial dysfunction, Celeste shifts Parkinson’s treatment beyond symptomatic relief. Its non-invasive, at-home design may improve adherence and quality of life while reducing drug burden. Success in Phase 3 could establish phototherapy as a new class of neurotherapeutic interventions.